The STAMPEDE trial and celecoxib: How to adapt?

The Lancet Oncology

Volumn 13, Issue 5, 2012, Pages 443-445

  Armstrong, Andrew J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG MECHANISM; FAILURE FREE SURVIVAL; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; PROSTATIC NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 84860454612     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70111-0     Document Type: Letter

References (9)

1. James ND, Sydes MR, Mason MD, et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 2012, publised online March 26. 10.1016/S1470-2045(12)70088-8.
2. James ND, Sydes MR, Clarke NW, et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int 2009, 103:464-469.
3. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
4. Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. Proc Am Soc Clin Oncol 2010, 28(suppl 18). abstr LBA4511.
5. Katz MS, Carroll PR, Cowan JE, et al. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int 2010, 106:627-632.
6. Khor LY, Bae K, Pollack A, et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 2007, 8:912-920.
7. Antonarakis ES, Heath EI, Walczak JR, et al. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol 2009, 27:4986-4993.
8. McGettigan P, Henry D Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011, 8:e1001098.
9. Keating NL, O'Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010, 102:39-46.